

Seeking Novel CNS Indications and Mechanistic Pathways for RIPK1 Inhibition

A global pharmaceutical company has developed a CNS-penetrant **receptor-interacting protein kinase 1 (RIPK1) inhibitor** and is actively seeking partners with expertise in RIPK1's role in human pathophysiology to **identify promising disease indications** that will guide further development of the inhibitor.



Approaches of Interest:

- Identification of promising CNS disease indications that are driven by the RIPK1 pathway for inhibitor development:
 - Both **genetic rare diseases and common diseases** are acceptable
 - For common diseases, **information that supports patient stratification**—identifying the specific population in which RIPK1 inhibitors demonstrate the most pronounced efficacy—is of high interest
 - Symptoms/pathophysiology that are associated with increased RIPK1 kinase activity or are improved by inhibition of RIPK1 kinase activity in clinical/non-clinical research
- **Pathways modulated by RIPK1 inhibitors** beyond inflammation and necroptosis in the CNS
- Approaches incorporating **RIPK3 and MLKL kinases** that are directly involved in RIPK1 kinase signaling are also of interest

Out of Scope:

- Indications that have already progressed to clinical trials such as ALS, MS, IBD, psoriasis, rheumatoid arthritis, and peripheral artery disease
- Research relating to ischemic stroke, Krabbe disease and Niemann-Pick disease type C
- Opportunities where RIPK1 functions as a protein scaffold

Developmental Stages of Interest:

- Research at basic to late preclinical stages is within scope
- Opportunities with *in vivo* validation are of highest interest

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this [submission form](#). In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Please check your organization's external collaboration policy and/or guidelines before submitting to this anonymous campaign, which may result in introduction and subsequent partnering discussions with the client company. Please get in touch with campaigns@inpart.io if you have any queries.

Opportunities sought

-  Biotech assets
-  Spinout companies
-  Research projects
-  Centres of excellence
-  Academics and expertise
-  Technologies

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **30th June 2025 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk